Anthropic sets out its biopharma ambitions in IPO doc
Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
Newsletters and Deep Dive digital magazine
Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.
What constitutes a reliable supply chain is changing rapidly.
AstraZeneca's CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers reveals a 53% reduction in the risk of death.
pharmaphorum spoke with Andreas Wolf, chief technology officer at numares Health about NMR-based lipoprotein profiling and cardiovascular disease.
Editor's Picks
Newsletters and Deep Dive
digital magazine